The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Pediatric autoimmune neuropsychiatric disorders associated with or without streptococcal and other bacterial infections (PANDAS/CANS) are emerging as a featured pediatric disorder. Although there is some controversy regarding treatment approaches, especially related to the behavioral sequelae, we have hypothesized in other published work that it is characterized by the rapid onset of Reward Deficiency Syndrome (RDS) in children. We propose utilizing a multi-systems biological approach involving the coupling of genetic addiction risk testing and pro-dopamine regulation (KB220/POLYGEN？) to help induce “dopamine homeostasis” in patients with PANDAS, especially those with known DNA-induced hypodopaminergia. This case study examines a 12-year-old Caucasian male with no prior psychiatric issues who presented with a sudden onset of severe anxiety, depression, emotional liability, and suicidal ideation. The patient underwent genotyping and the genetic addiction risk score (GARS) testing, which revealed risk polymorphisms in the dopamine D2 (-DRD2/ANKK (Taq1A), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) genes. These polymorphisms have been linked to hypodopaminergia. The patient was subsequently placed on research ID-KB220ZPBMPOLY (POLYGEN？), and albeit the possibility of bias, based upon self and parental assessment, a marked rapid improvement in psychiatric symptoms was observed. In the second phase of treatment (102 days utilizing KB220), the patient received standard antibody testing, which was positive for Lyme. Antibacterial therapy started immediately, and KB220z was discontinued to provide a wash-out period. A monotonic trend analysis was performed on each outcome measure, and a consistently decreasing trend was observed utilizing antibacterial therapy. Our recommendation, albeit only one case, is to utilize and further research a combined therapeutic approach, involving precision-guided DNA testing and pro-dopamine regulation along with antibacterial therapy, as well as glutathione to address offensive enhanced cytokines, in patients with suspected PANDAS/CANS.
References
[1]
Moretti, G., Pasquini, M., Mandarelli, G., Tarsitani, L. and Biondi, M. (2008) What Every Psychiatrist Should Know about PANDAS: A Review. ClinicalPracticeandEpidemiologyinMentalHealth, 4, Article No. 13. https://doi.org/10.1186/1745-0179-4-13
[2]
Fallon, B.A., Madsen, T., Erlangsen, A. and Benros, M.E. (2021) Lyme Borreliosis and Associations with Mental Disorders and Suicidal Behavior: A Nationwide Danish Cohort Study. AmericanJournalofPsychiatry, 178, 921-931. https://doi.org/10.1176/appi.ajp.2021.20091347
[3]
Madigan, M., Gupta, A., Bowirrat, A., Baron, D., Badgaiyan, R., Elman, I., etal. (2022) Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence? InternationalJournalofEnvironmentalResearchandPublicHealth, 19, Article 6395. https://doi.org/10.3390/ijerph19116395
[4]
Blum, K., Modestino, E.J., Febo, M., Steinberg, B., McLaughlin, T., Fried, L., etal. (2017) Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission. JournalofSystemsandIntegrativeNeuroscience, 3, 1-4. https://doi.org/10.15761/jsin.1000163
[5]
Pichichero, M.E. (2008) The PANDAS Syndrome. In: Finn, A., Curtis, N. and Pollard, A., Eds., Hot Topics in Infection and Immunity in Children V, Springer, 205-216. https://doi.org/10.1007/978-0-387-79838-7_17
[6]
Marazziti, D., Mucci, F. and Fontenelle, L.F. (2018) Immune System and Obsessive-Compulsive Disorder. Psychoneuroendocrinology, 93, 39-44. https://doi.org/10.1016/j.psyneuen.2018.04.013
[7]
Leckman, J.F., Denys, D., Simpson, H.B., Mataix-Cols, D., Hollander, E., Saxena, S., etal. (2010) Obsessive-Compulsive Disorder: A Review of the Diagnostic Criteria and Possible Subtypes and Dimensional Specifiers for DSM-V. DepressionandAnxiety, 27, 507-527. https://doi.org/10.1002/da.20669
[8]
Kurlan, R. and Kaplan, E.L. (2004) The Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS) Etiology for Tics and Obsessive-Compulsive Symptoms: Hypothesis or Entity? Practical Considerations for the Clinician. Pediatrics, 113, 883-886. https://doi.org/10.1542/peds.113.4.883
[9]
Shprecher, D. and Kurlan, R. (2009) The Management of Tics. MovementDisorders, 24, 15-24. https://doi.org/10.1002/mds.22378
[10]
Singer, H.S. (2011) Tourette Syndrome and Other Tic Disorders. HandbookofClinicalNeurology, 11, 641-657. https://doi.org/10.1016/b978-0-444-52014-2.00046-x
[11]
Singer, H.S., Gilbert, D.L., Wolf, D.S., Mink, J.W. and Kurlan, R. (2012) Moving from PANDAS to Cans. TheJournalofPediatrics, 160, 725-731. https://doi.org/10.1016/j.jpeds.2011.11.040
[12]
Blum, K., Thanos, P.K., Badgaiyan, R.D., Febo, M., Oscar-Berman, M., Fratantonio, J., Demetrovics, Z. and Gold, M.S. (2022) Neurogenetics and Gene Therapy for Reward Deficiency Syndrome: Are We Going to the Promised Land? Expert Opinion on Biological Therapy, 15, 973-985. https://doi.org/10.1517/14712598.2015.1045871
[13]
Kulumani Mahadevan, L.S., Murphy, M., Selenica, M., Latimer, E. and Harris, B.T. (2023) Clinicopathologic Characteristics of PANDAS in a Young Adult: A Case Report. DevelopmentalNeuroscience, 45, 335-341. https://doi.org/10.1159/000534061
[14]
Xie, K., Chai, Y., Lin, S., Xu, F. and Wang, C. (2021) Luteolin Regulates the Differentiation of Regulatory T Cells and Activates IL-10-Dependent Macrophage Polarization against Acute Lung Injury. Journal of Immunology Research, 2021, Article 8883962. https://doi.org/10.1155/2021/8883962
[15]
Blum, K., Bowirrat, A., Baron, D., Lott, L., Ponce, J.V., Brewer, R., etal. (2020) Biotechnical Development of Genetic Addiction Risk Score (GARS) and Selective Evidence for Inclusion of Polymorphic Allelic Risk in Substance Use Disorder (SUD). JournalofSystemsandIntegrativeNeuroscience, 6, 1-20. https://doi.org/10.15761/jsin.1000221
[16]
Blum, K., Ashford, J.W., Kateb, B., Sipple, D., Braverman, E., Dennen, C.A., et al. (2012) Dopaminergic Dysfunction: Role for Genetic & Epigenetic Testing in the New Psychiatry. Journal of the Neurological Sciences, 453, Article 120809. https://doi.org/10.1016/j.jns.2023.120809
[17]
Blum, K., Kazmi, S., Modestino, E.J., Downs, B.W., Bagchi, D., Baron, D., etal. (2021) A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. JournalofPersonalizedMedicine, 11, Article 212. https://doi.org/10.3390/jpm11030212
[18]
Blum, K. (2016) Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) Can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence. ClinicalMedicalReviewsandCaseReports, 3, Article 125. https://doi.org/10.23937/2378-3656/1410125
[19]
Sigra, S., Hesselmark, E. and Bejerot, S. (2018) Treatment of PANDAS and PANS: A Systematic Review. Neuroscience&BiobehavioralReviews, 86, 51-65. https://doi.org/10.1016/j.neubiorev.2018.01.001
[20]
Blum, K., Han, D., Gupta, A., Baron, D., Braverman, E.R., Dennen, C.A., etal. (2022) Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects. JournalofPersonalizedMedicine, 12, Article 1385. https://doi.org/10.3390/jpm12091385
[21]
Blum, K. (2017) Dopamine Homeostasis Brain Functional Connectivity in Reward Deficiency Syndrome. FrontiersinBioscience, 22, 669-691. https://doi.org/10.2741/4509
[22]
Blum, K., Dennen, C.A., Braverman, E.R., Gupta, A., Baron, D., Downs, B.W., etal. (2022) Hypothesizing that Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”. OpenJournalofImmunology, 12, 65-75. https://doi.org/10.4236/oji.2022.123004
[23]
Endres, D., Pollak, T.A., Bechter, K., Denzel, D., Pitsch, K., Nickel, K., etal. (2022) Immunological Causes of Obsessive-Compulsive Disorder: Is It Time for the Concept of an “Autoimmune OCD” Subtype? TranslationalPsychiatry, 12, Article No. 5. https://doi.org/10.1038/s41398-021-01700-4
[24]
Cocuzza, S., Maniaci, A., La Mantia, I., Nocera, F., Caruso, D., Caruso, S., etal. (2022) Obsessive-Compulsive Disorder in PANS/PANDAS in Children: In Search of a Qualified Treatment—A Systematic Review and Metanalysis. Children, 9, Article 155. https://doi.org/10.3390/children9020155
[25]
Hutanu, A., Reddy, L.N., Mathew, J., Avanthika, C., Jhaveri, S. and Tummala, N. (2022) Pediatric Autoimmune Neuropsychiatric Disorders Associated with Group a Streptococci: Etiopathology and Diagnostic Challenges. Cureus, 14, e27729. https://doi.org/10.7759/cureus.27729
[26]
Trifonova, E.A., Mustafin, Z.S., Lashin, S.A. and Kochetov, A.V. (2022) Abnormal mTOR Activity in Pediatric Autoimmune Neuropsychiatric and MIA-Associated Autism Spectrum Disorders. InternationalJournalofMolecularSciences, 23, Article 967. https://doi.org/10.3390/ijms23020967
[27]
O’Dor, S.L., Zagaroli, J., Belisle, R., Hamel, M., Downer, O., Homayoun, S., etal. (2022) The COVID-19 Pandemic and Children with PANS/PANDAS: An Evaluation of Symptom Severity, Telehealth, and Vaccination Hesitancy. ChildPsychiatry&HumanDevelopment, 55, 327-335. https://doi.org/10.1007/s10578-022-01401-z
[28]
Prus, K., Weidner, K. and Alquist, C. (2022) Therapeutic Plasma Exchange in Adolescent and Adult Patients with Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. JournalofClinicalApheresis, 37, 597-599. https://doi.org/10.1002/jca.22023
[29]
Aman, M., Coelho, J.S., Lin, B., Lu, C., Westwell-Roper, C., Best, J.R., etal. (2022) Prevalence of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) in Children and Adolescents with Eating Disorders. JournalofEatingDisorders, 10, Article No. 194. https://doi.org/10.1186/s40337-022-00707-6
[30]
Ellerkamp, H., Thienemann, M., Tinero, J., Shaw, R., Dowtin, L.L., Frankovich, J., etal. (2022) Group Psychotherapy for Parents of Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome. JournalofClinicalPsychologyinMedicalSettings, 30, 660-672. https://doi.org/10.1007/s10880-022-09926-0
[31]
Gromark, C., Hesselmark, E., Djupedal, I.G., Silverberg, M., Horne, A., Harris, R.A., etal. (2021) A Two-to-Five Year Follow-Up of a Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort. ChildPsychiatry&HumanDevelopment, 53, 354-364. https://doi.org/10.1007/s10578-021-01135-4
[32]
Efe, A. (2022) SARS-CoV-2/COVID-19 Associated Pediatric Acute-Onset Neuropsychiatric Syndrome a Case Report of Female Twin Adolescents. PsychiatryResearchCaseReports, 1, Article 100074. https://doi.org/10.1016/j.psycr.2022.100074
[33]
Blum, K., Oscar-Berman, M., Stuller, E., Miller, D., Giordano, J., Morse, S., et al. (2012) Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. Journal of Addiction Research & Therapy, 3, Article 139. https://doi.org/10.4172/2155-6105.1000139
[34]
Blum, K., Steinberg, B., Gondré-Lewis, M.C., Baron, D., Modestino, E.J., Badgaiyan, R.D., etal. (2021) A Review of DNA Risk Alleles to Determine Epigenetic Repair of Mrna Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”. PsychologyResearchandBehaviorManagement, 14, 2115-2134. https://doi.org/10.2147/prbm.s292958
[35]
Abijo, T., Blum, K. and Gondré-Lewis, M.C. (2020) Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) as a Function of Ethnicity: Relevance to Precision Addiction Medicine. CurrentNeuropharmacology, 18, 578-595. https://doi.org/10.2174/1570159x17666191118125702
[36]
Blum, K., McLaughlin, T., Bowirrat, A., Modestino, E.J., Baron, D., Gomez, L.L., etal. (2022) Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”? JournalofPersonalizedMedicine, 12, Article 321. https://doi.org/10.3390/jpm12020321
[37]
Blum, K., Sheridan, P.J., Wood, R.C., Braverman, E.R., Chen, T.J.H., etal. (1996) The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome. JournaloftheRoyalSocietyofMedicine, 89, 396-400. https://doi.org/10.1177/014107689608900711
[38]
Blum, K., Modestino, E.J., Gondre-Lewis, M.C., Baron, D., Steinberg, B., Thanos, P.K., et al. (2018) Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated). CPQ Neurology and Psychology, 1. https://www.cientperiodique.com/journal/fulltext/CPQNP/1/2/13
[39]
Blum, K., Baron, D., McLaughlin, T., Thanos, P.K., Dennen, C., Ceccanti, M., et al. (2022) Summary Document Research on RDS Anti-Addiction Modeling: Annotated Bibliography. Journal of Systems and Integrative Neuroscience, 8, 2-35.
